Screener
Vir Biotechnology, Inc. VIR Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value
Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue.
The source filing: Vir Biotechnology, Inc.’s 10-K, filed February 23, 2026. Open the filing →
- Filed
- Feb 23, 2026, 5:27 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-010749
FAQ
- What is Vir Biotechnology, Inc.'s increase decrease in payment of contingent consideration in excess of acquisition date fair value?
- Vir Biotechnology, Inc. (VIR) reported increase decrease in payment of contingent consideration in excess of acquisition date fair value of -$4.29M in Q4 2025.
- What does increase decrease in payment of contingent consideration in excess of acquisition date fair value mean?
- Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value as reported by Vir Biotechnology, Inc. Common Stock.
Ask your AI about Vir Biotechnology, Inc.'s increase decrease in payment of contingent consideration in excess of acquisition date fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude